Xiangcheng Zhang

1 clinical trials · Sponsor

Record	Firm	Date
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury. (NCT06001294)	Xiangcheng Zhang	2022-07-03

Every clearance here is in the API, with alerts when new ones post.